Content » Vol 101, March

Clinical Report

Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study

Marina Talamonti, Giovanna Malara, Ylenia Natalini, Federico Bardazzi, Andrea Conti, Andrea Chiricozzi, Cristina Mugheddu, Paolo Gisondi, Stefano Piaserico, Gianluca Pagnanelli, Paolo Amerio, Concetta Potenza, Franca Cantoresi, Maria Concetta Fargnoli, Anna Balato, Francesco Loconsole, Annamaria Offidani, Claudio Bonifati, Francesca Prignano, Marta Bartezaghi, Alice Rausa, Elisabetta Aloisi, Roberto Orsenigo, Antonio Costanzo, for the SUPREME Study Group
DOI: 10.2340/00015555-3712


This study evaluated whether secukinumab treatment for patients with moderate to severe plaque psoriasis correlates with improvements in symptoms of anxiety and depression. SUPREME was a 24-week, phase IIIb, multicentre, prospective study conducted across 50 centres in Italy with an extension period of up to 72 weeks. Assessments used were: Psoriasis Area Sever­ity Index (PASI), Hospital Anxiety and Depression Scale (HADS) – Anxiety (HADS-A), and HADS – Depression (HADS-D) scores and Dermatology Quality Life Index (DLQI). Compared with baseline, a significantly greater proportion of patients who reported moderate to severe clinical symptoms of anxiety or depression (HADS-A or HADS-D ≥ 11) were free of moderate to severe symptoms at weeks 16 and 48. The PASI and DLQI scores reduced over time with secukinumab treatment. Psoriasis treatment with secukinumab for 48 weeks resulted in significantly improved skin clearance and a parallel improvement in symptoms of anxiety and depression, assessed by HADS.


Improvements in psoriatic symptoms may improve anxiety and depression symptoms in patients with psoriasis, who also suffer from these psychiatric disorders. We evaluated whether secukinumab treatment, over 48 weeks, might improve anxiety and depression symptoms in patients with moderate to severe plaque psoriasis who participated in the SUPREME clinical trial. Our findings show that 66.7% and 70.6% of patients changed their status from having symptoms of anxiety at baseline to not having anxiety symptoms at Weeks 16 and 48, respectively. Similarly, 81.3% and 70.6% of patients exhibited improvement in symptoms of depression at weeks 16 and 48, respectively.

Supplementary content


Not logged in! You need to login/create an account to comment on articles. Click here to login/create an account.